AnPac Bio appoints Dr. Aidong Chen as CEO and Board Chairman alongside Dorothy Liu joining as Board Member

– USA, CA –  AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection, today announced the appointment of Dr. Aidong Chen to its board director as CEO and Chairman of the Board of Directors, replacing founder Dr. Chris Yuwho resigned from his role but Dr. Yu will remain with the Company in a senior management role to focus on growing business in China.

The Company also announced the addition of Dorothy Liu to its Board of Directors, replacing Chao Feng.

About Dr. Aidong Chen

Dr. Aidong Chen has been a practicing physician and researcher for over 10 years. He has received over 20 global patents on his work and published 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University.

About Sheng Liu

Ms. Liu is currently the CEO of Zhongjintai Venture Capital Co., Ltd., a venture capital firm in Shenzhen. She has worked in finance and consulting, including in private equity, for almost ten years. Ms. Liu will be an independent director and will also serve as a member of the Compensation Committee and Chairperson of the Nominating Committee.

About AnPac Bio

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 150 issued patents as of September 30, 2021. With two certified clinical laboratories in China and one CLIA and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological, and genomics tests. According to a report by Frost & Sullivan, AnPac Bio ranked first globally in multi-cancer screening and detection test sample volume (accumulative to January 2021). AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For more information: https://www.anpacbio.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team